OCGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

860.00K

+12.57%

-0.058

+15%

500.00K

-66.24%

-0.060

+20%

550.00K

-59.94%

-0.057

+13.34%

Estimates Revision

The market is revising Upward the revenue expectations for Ocugen, Inc. (OCGN) for FY2025, with the revenue forecasts being adjusted by 37.75% over the past three months. During the same period, the stock price has changed by -12.28%.

Revenue Estimates for FY2025

Revise Upward

+37.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.81%

In Past 3 Month

Stock Price

Go Down

-12.28%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 9.00 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

9.00

High

15.00

Current: 0.000

Low

4.00

Averages

9.00

High

15.00

Lucid Capital

Elemer Piros

Buy

initiated

$15

2025-09-30

Reason

Lucid Capital

Elemer Piros

Price Target

$15

2025-09-30

initiated

Buy

Reason

Lucid Capital analyst Elemer Piros initiated coverage of Ocugen with a Buy rating and $15 price target. Ocugen is developing next-generation, genetic medicines with the intention to save vision in genetic disorders of the eye, the analyst tells investors in a research note. The firm believes OCU400 in retinitis pigmentosa could see peak sales of $3.2B by 2032.

H.C. Wainwright

Buy

downgrade

$8 -> $7

2025-05-12

Reason

H.C. Wainwright

Price Target

$8 -> $7

2025-05-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Ocugen to $7 from $8 and keeps a Buy rating on the shares following the Q1 report. The firm says the company is targeting OCU400 approval in 2026.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-06

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-06

Reiterates

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$6 → $7

2025-03-06

Reason

Chardan Capital

Daniil Gataulin

Price Target

$6 → $7

2025-03-06

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Maintains

$7 → $8

2025-02-13

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$7 → $8

2025-02-13

Maintains

Strong Buy

Reason

Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 70.69% +1.20, Soho House + Co Inc (SHCO) 1.61% +0.98, X4 Pharmaceuticals (XFOR) 2.32% +0.68, Autobot Holdings (ARBE) 8.92% +0.42, Gorilla Technology Group Inc (GRRR) 35.63% +0.29, Ocugen (OCGN) 2.92% +0.28, Plug Power (PLUG) 8.36% +0.22, Equinor (EQNR) 4.81% +0.21, Hecla Mining (HL) 0.58% +0.20, and SolarEdge (SEDG) 0.83% +0.19.

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

2025-02-13

Reason

Chardan Capital

Daniil Gataulin

Price Target

2025-02-13

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Ocugen Inc (OCGN.O) is -5.98, compared to its 5-year average forward P/E of -27.18. For a more detailed relative valuation and DCF analysis to assess Ocugen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.18

Current PE

-5.98

Overvalued PE

73.47

Undervalued PE

-127.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

154.77

Current PS

171.71

Overvalued PS

385.71

Undervalued PS

-76.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OCGN News & Events

Events Timeline

No data

News

1.0

01-09Globenewswire

Ocugen to Present Gene Therapy Progress at J.P. Morgan Healthcare Conference

1.0

2025-12-10Newsfilter

Ocugen to Present at Oppenheimer Rare Disease Summit on December 11

6.5

2025-11-30Yahoo Finance

Changing Perspectives on Ocugen Following Recent Licensing and Analyst Updates

People Also Watch

Frequently Asked Questions

What is Ocugen Inc (OCGN) stock price today?

The current price of OCGN is 1.5 USD — it has increased 0.67 % in the last trading day.

What is Ocugen Inc (OCGN)'s business?

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

What is the price predicton of OCGN Stock?

What is Ocugen Inc (OCGN)'s revenue for the last quarter?

Ocugen Inc revenue for the last quarter amounts to 1.75M USD, increased 54.23 % YoY.

What is Ocugen Inc (OCGN)'s earnings per share (EPS) for the last quarter?

Ocugen Inc. EPS for the last quarter amounts to -0.07 USD, increased 40.00 % YoY.

What changes have occurred in the market's expectations for Ocugen Inc (OCGN)'s fundamentals?

How many employees does Ocugen Inc (OCGN). have?

Ocugen Inc (OCGN) has 95 emplpoyees as of January 10 2026.

What is Ocugen Inc (OCGN) market cap?

Today OCGN has the market capitalization of 468.48M USD.